REGN10597 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is Regeneron Pharmaceuticals. Registered phases: Phase 2 and Phase 1/2. Conditions studied include Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
Phase 2 | Recruiting |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (ClinicalTrials.gov ↗) Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Primary Peritoneal Cancer | 1 |
| Melanoma | 1 |
| Clear-Cell Renal-Cell Carcinoma (ccRCC) | 1 |
| Advanced Solid Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 2 |
| Register | REGN10597 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how REGN10597 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists REGN10597 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.